Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2014
02/06/2014WO2014021393A1 Transdermal absorption-type pharmaceutical preparation comprising zonisamide
02/06/2014WO2014021383A1 Condensed ring heterocyclic compound
02/06/2014WO2014021337A1 Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
02/06/2014WO2014021306A1 Medicine against gastroesophageal reflux disease
02/06/2014WO2014021284A1 Anti-trichophytic adhesive patch
02/06/2014WO2014021282A1 Antitrichophytosis solution for external use
02/06/2014WO2014021281A1 Partially saturated nitrogen-containing heterocyclic compound
02/06/2014WO2014021273A1 Morphinan derivatives
02/06/2014WO2014020608A1 Methods of diagnosing and treating motor neuron diseases
02/06/2014WO2014020577A1 Novel compounds which activate sirt1 enzymatic activity and pharmaceutical or cosmetic compositions comprising same
02/06/2014WO2014020553A1 Salts of pralatrexate
02/06/2014WO2014020546A2 Crystalline forms of dabigatran etexilate and process for their preparation
02/06/2014WO2014020531A1 Imidazo[1,2-b]pyridazin-6-amine derivatives as kinase jak-2 inhibitors
02/06/2014WO2014020516A1 Antibacterial composition for topical use
02/06/2014WO2014020458A1 Improved process for preparation of rivaroxaban
02/06/2014WO2014020408A1 Compositions for a medical device comprising exopolysaccharide-producing bacterial strains in association with gums and/or gelatines
02/06/2014WO2014020405A1 Cyclic urea- or lactam-substituted quinoxaline-type piperidine compounds and the uses thereof
02/06/2014WO2014020381A1 Novel crystalline form of azilsartan medoxomil potassium
02/06/2014WO2014020366A1 Transdermal formulation containing cox inhibitors
02/06/2014WO2014020351A1 Receptor antagonists
02/06/2014WO2014020350A1 Par2 receptor antagonists
02/06/2014WO2014020344A1 Compounds and their effects on appetite control and insulin sensitivity
02/06/2014WO2014020339A1 Methods and compositions for inhibiting sea lice
02/06/2014WO2014020227A1 Method for obtaining low molecular weight and very low molecular weight heparins
02/06/2014WO2014020226A1 Additives for feeding aquatic animals, containing probiotics
02/06/2014WO2014020224A1 Method for preventing and/or controlling bacterial infections
02/06/2014WO2014020160A1 Article of manufacture comprising aflibercept or ziv-aflibercept
02/06/2014WO2014020156A1 Combination therapy for treatment of multiple sclerosis
02/06/2014WO2014020155A1 Oral transmucosal adminstration forms of s-ketamine
02/06/2014WO2014020105A1 Griseofulvin derivatives
02/06/2014WO2014020101A1 Griseofulvin derivatives
02/06/2014WO2014020043A1 Combinations for the treatment of cancer
02/06/2014WO2014020041A1 Combinations for the treatment of cancer
02/06/2014WO2014020039A1 Lozenges with multiple release kinetics for active ingredients
02/06/2014WO2014020031A1 Composition comprising a sucrose octasulphate and a specific emollient
02/06/2014WO2014020012A1 Quinone compounds and their uses for the treatment of cancer
02/06/2014WO2014019994A1 Use of 6-methyl-5-heptene-2-one in a timed insemination method for mammals
02/06/2014WO2014019979A1 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
02/06/2014WO2014019972A1 Injectable compositions comprising letrozole or anastrozole
02/06/2014WO2014019967A1 N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof
02/06/2014WO2014019919A1 Pharmaceutical compositions comprising 15-ohepa and methods of using the same
02/06/2014WO2014019908A2 Substituted pyrroles active as kinases inhibitors
02/06/2014WO2014019855A1 Method for preparing creatine fatty esters, creatine fatty esters thus prepared and uses thereof
02/06/2014WO2014019685A1 Novel chartreusin analogues
02/06/2014WO2014019556A1 Alaptide : methods of effecting its solubility, membrane permeation and pharmaceutical compositions for human and/or veterinary applications
02/06/2014WO2014019486A1 New application of patchouli oil
02/06/2014WO2014019485A1 New application of pogostone
02/06/2014WO2014019468A1 Piperazinotrizole compound, preparation method therefor, and use thereof in drug preparation
02/06/2014WO2014019452A1 Physical antimicrobial method
02/06/2014WO2014019442A1 Benzofuran derivatives, preparation method and medical use thereof
02/06/2014WO2014019344A1 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
02/06/2014WO2014019338A1 Protein kinase inhibitors
02/06/2014WO2014019282A1 Meropenem bulk drug, preparation method thereof and pharmaceutical composition containing same
02/06/2014WO2014019268A1 Pharmaceutical composition for promoting nerve injury restoration and application thereof
02/06/2014WO2014019186A1 Antidiabetic tricyclic compounds
02/06/2014WO2014019095A1 Resiniferatoxin solution
02/06/2014WO2014019092A1 Inhibitors of peptidyl arginine deiminase (pad) enzymes and uses thereof
02/06/2014WO2014019044A1 Hydrazide-n-acylhydrazone compounds, method for producing hydrazide-n-acylhydrazone compounds, use of intermediate compounds for producing hydrazide-n-acylhydrazones fof the treatment of leishmaniasis and chagas disease, and thus obtained pharmaceutical compositions
02/06/2014WO2014019023A1 α7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
02/06/2014WO2013188279A8 Topical ophthalmological pharmaceutical composition containing cediranib
02/06/2014WO2013186792A3 Process for preparation of azilsartan medoxomil and its salts
02/06/2014WO2013182451A9 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
02/06/2014WO2013173583A8 Psma inhibitors
02/06/2014WO2013171729A3 Aryl and heteroaryl amide compounds as ror gamma t modulator
02/06/2014WO2013170367A8 Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors
02/06/2014WO2013169793A3 Methods and compositions for tdp-43 proteinopathies
02/06/2014WO2013102144A3 Ph20 polypeptide variants, formulations and uses thereof
02/06/2014WO2013012199A8 Capsule formulation comprising montelukast and levocetirizine
02/06/2014US20140039454 Methods of treating subchondral bone to prevent the progression of osteoarthritis in joints
02/06/2014US20140039179 Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
02/06/2014US20140039070 Compositions and methods of delivery of pharmacological agents
02/06/2014US20140039069 Compositions and methods of delivery of pharmacological agents
02/06/2014US20140039065 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
02/06/2014US20140039063 Leukotrienes and asthma exacerbation risk
02/06/2014US20140039062 Injectable device and method for sculpting, augmenting or correcting facial features such as the chin
02/06/2014US20140039061 Hyaluronic acid composition
02/06/2014US20140039059 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
02/06/2014US20140039058 Ophthalmic solution
02/06/2014US20140039057 Compositions
02/06/2014US20140039054 Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss
02/06/2014US20140039053 Therapeutic agent for diastolic congestive heart failure
02/06/2014US20140039052 Formulations of lipophilic bioactive molecules
02/06/2014US20140039047 Methods for regulating sirtuin gene expression
02/06/2014US20140039046 Compositions and products containing s-equol, and methods for their making
02/06/2014US20140039045 Composition of monoterpenoids having bactericidal properties
02/06/2014US20140039044 Hydroxylated Polymethoxyflavone Compositions
02/06/2014US20140039043 Pharmaceutical compositions comprising cannabigerol
02/06/2014US20140039040 Analgesic method
02/06/2014US20140039039 Organic compositions to treat hsf1-related diseases
02/06/2014US20140039032 Lipid nano particles comprising cationic lipid for drug delivery system
02/06/2014US20140039031 Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
02/06/2014US20140039030 Polymer-des-ethyl sunitinib conjugates
02/06/2014US20140039029 Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
02/06/2014US20140039028 Transdermal formulation containing cox inhibitors
02/06/2014US20140039024 Novel compounds as opioid receptor modulators
02/06/2014US20140039022 Manufacture, compositions and uses of coagulation factor viia modulator
02/06/2014US20140039019 Methods of Using Ryanodine Antagonists in Treating Neural Injury
02/06/2014US20140039017 Therapeutic combination
02/06/2014US20140039015 Methods of using sustained release aminopyridine compositions
02/06/2014US20140039012 Compounds Having CRTH2 Antagonist Activity
1 ... 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 ... 7860